Article Text

PDF
Checkpoint inhibitors and arthritis
  1. Nicholas Manolios1,2,
  2. Leslie Schrieber1,3
  1. 1Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia
  2. 2Department of Rheumatology, Westmead Hospital, Sydney, New South Wales, Australia
  3. 3Department of Rheumatology, Royal North Shore Hospital, Sydney, New South Wales, Australia
  1. Correspondence to Professor Nicholas Manolios, University of Sydney, Sydney, NSW 2006, Australia; nicholas.manolios{at}sydney.edu.au

Statistics from Altmetric.com

It was with interest that we read the article by Belkhir et al1 in the recent Annals of Rheumatic Disease. The article described the first report of rheumatoid arthritis (RA) and polymyalgia rheumatica developing after the use of immune checkpoint inhibitors to treat a variety of cancers. We found the article interesting and informative but noted that in all of their 10 reported cases, the patients seroconverted from rheumatoid factor (RF) or cyclic citrullinated peptide antibody (CCP) negative to positive, supporting their claim that ‘rheumatoid arthritis’ may develop after immune checkpoint inhibitor treatment.

The report by Belkhir et al is in contrast to our experience managing …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.